Samsung BioLogics, Bristol enter manufacturing deal for melanoma drug

07/31/2013 | PharmaTimes (U.K.)

Samsung BioLogics signed a 10-year deal to manufacture Bristol-Myers Squibb's melanoma drug Yervoy, or ipilimumab, at its facility in Songdo Incheon, South Korea. Samsung is beginning trial production, and commercial production will follow the securing of regulatory OKs.

View Full Article in:

PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Santa Clara, CA
Director, Site Quality Management
Minneapolis, MN